Your browser doesn't support javascript.
loading
Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation.
Zhou, Hao; Lin, Jian; Chen, Shushang; Ma, Liqiang; Qiu, Zhenzhen; Chen, Weidong; Zhang, Xin'an; Zhang, Yi; Lin, Xiuquan.
Affiliation
  • Zhou H; Department of Urology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine (The People's Hospital of Fujian Province), No. 602, Middle Road 817, Fuzhou, 350004, China. okhao@hotmail.com
Clin Exp Nephrol ; 17(2): 304-9, 2013 Apr.
Article in En | MEDLINE | ID: mdl-23053591
BACKGROUND: Good outcomes after renal transplantation are dependent on effective immunosuppression while minimizing infection. Alemtuzumab (Campath or Campath-1H) is an anti-CD52 humanized monoclonal IgG1 antibody which induces rapid and sustained depletion of circulating lymphocytes and has been effectively used as an immunosuppressant in post-transplant induction therapy. METHODS: We used the ImmuKnow assay to compare cell-mediated immune function in renal transplant patients treated with alemtuzumab or with conventional immunosuppressive tri-therapy. The ImmuKnow method determines the levels of adenosine triphosphate (ATP) released from CD4 cells following stimulation with a mitogen. RESULTS: We showed a statistically significant difference in the distribution of outcome after transplantation between the conventional and the Campath groups (P = 0.010). A significantly higher number of patients treated with alemtuzumab induction therapy were stable after transplantation compared to those treated with conventional immunosuppressive tri-therapy (96.6 vs. 75.7 %). ATP values were significantly higher in the conventional group compared to the Campath group at 180 days after transplantation (P < 0.001). ATP levels did not change significantly over time in clinically stable kidney recipients treated with alemtuzumab induction therapy (P = 0.554). CONCLUSIONS: The ImmuKnow assay is a useful tool for evaluating the global immune response in alemtuzumab-treated renal transplant patients. Alemtuzumab-depleting induction therapy remains effective for at least 180 days.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoassay / Immunosuppression Therapy / Kidney Transplantation / Antibodies, Monoclonal, Humanized / Immunity, Cellular / Antineoplastic Agents Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Nephrol Journal subject: NEFROLOGIA Year: 2013 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoassay / Immunosuppression Therapy / Kidney Transplantation / Antibodies, Monoclonal, Humanized / Immunity, Cellular / Antineoplastic Agents Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Nephrol Journal subject: NEFROLOGIA Year: 2013 Document type: Article Affiliation country: Country of publication: